COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Coversin (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Acronyms COBALT
- Sponsors Akari Therapeutics
- 08 Dec 2017 Results published in the Akari Therapeutics media release.
- 08 Dec 2017 Primary endpoint of Reduction in serum LDH to less than or equal to 1.8 times the upper limit of normal has been met, according to an Akari Therapeutics media release.
- 04 Dec 2017 According to an Akari Therapeutics media release, data of this trial will be presented at an event being held at the Omni Atlanta Hotel at CNN Center on Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial History